We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease (CAN-GT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04833907
Recruitment Status : Active, not recruiting
First Posted : April 6, 2021
Last Update Posted : February 8, 2023
Information provided by (Responsible Party):
Myrtelle Inc.

Brief Summary:

Canavan Disease is a congenital white matter disorder caused by mutations to the gene encoding for aspartoacylase (ASPA). Expression of ASPA is restricted to oligodendrocytes, the sole white matter producing lineage in the brain. ASPA supports myelination in the capacity of its sole known function, namely, the catabolism of N-acetylaspartate (NAA). Inherited mutations that result in loss of ASPA catabolic activity result in a typically severe phenotype of Canavan Disease, characterized by chronically elevated brain NAA, gross motor abnormalities, hypomyelination, progressive spongiform degeneration of the brain, epilepsy, blindness, and a short life expectancy. Disease severity is correlated with residual levels of enzyme activity. Reconstitution of ASPA function in oligodendrocytes of the brains of Canavan patients is expected to rescue NAA metabolism in its natural cellular compartment and support myelination/remyelination by resident white matter producing cells. This protocol directly targets oligodendrocytes in the brain, which are intimately involved with disease initiation and progression. Targeting oligodendrocytes offers the safest and most direct therapy for affected individuals.

The latest generation AAV viral vector (rAAV-Olig001-ASPA) will be administered to patients using neurosurgical procedure which involves direct administration of gene therapy to affected regions of the brain. Outcome measures for the open label clinical trial include longitudinal clinical assessments and brain imaging.

Currently, there is no effective treatment for Canavan Disease. The purpose of this study is to validate a new technology targeted to the cells most affected by Canavan Disease in the safest way possible.

The study investigators are committed to supporting the Rare Disease & Canavan Disease Communities. For more information, please contact Jordana Holovach, Head of Communications and Community at PatientAdvocacy@myrtellegtx.com.

Condition or disease Intervention/treatment Phase
Canavan Disease Drug: rAAV-Olig001-ASPA Drug: Levetiracetam Drug: Prednisone Phase 1 Phase 2

Detailed Description:

rAAV-Olig001-ASPA is the first gene therapy designed to target the oligodendrocytes, which are critical for myelination and brain development.

This study is a Phase 1/2 First-In-Human protocol designed to obtain safety, pharmacodynamics, and efficacy data following neurosurgical administration of a single dose of rAAV-Olig001-ASPA delivered intracerebroventricularly in up to 24 children with Canavan Disease.

Patients with a diagnosis of typical Canavan Disease who meet all eligibility criteria may be enrolled in this open-label, sequential cohort study of a single dose of rAAV-Olig001-ASPA.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of AVASPA Gene Therapy for Treatment of Children With Typical Canavan Disease
Actual Study Start Date : April 1, 2021
Estimated Primary Completion Date : August 31, 2023
Estimated Study Completion Date : August 31, 2024

Arm Intervention/treatment
Experimental: 3.7 x 10^13 v.g. rAAV-Olig001-ASPA
3.7 x 10^13 v.g. of rAAV-Olig001-ASPA administered as a single dose neurosurgically to the brain via 2 pre-defined intracerebroventricular sites
Drug: rAAV-Olig001-ASPA
Intracerebroventricular administration of a single dose
Other Name: MYR-101

Drug: Levetiracetam
Keppra daily dose (20-50 mg/kg/day divided twice daily administered orally or per G-tube) in the post-operative period and continued for 3 months per standard of care to prevent seizure activity.
Other Name: Keppra

Drug: Prednisone
Post-operatively, a 3-month steroid taper is planned to prevent or reduce possible delayed immunological responses. This tapering regimen will consist of 0.5 mg/kg/day prednisone during weeks 1-4; followed by 0.3 mg/kg/day prednisone during weeks 5-8; and 0.1mg prednisone during weeks 9-12, then off. If there is evidence of new inflammation on MRI at 3-months on T2 FLAIR, the steroid taper will be extended for an additional 3 months or we will transition to steroid-sparing immunosuppression.

Primary Outcome Measures :
  1. Safety evaluation [ Time Frame: 12 Months Post Dose ]
    Number, severity, and causal relationship of any adverse event (to either the gene therapy and/or surgical trial procedures required for vector administration) using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

Secondary Outcome Measures :
  1. Myelination [ Time Frame: 12 Months Post Dose ]
    Change from baseline measured by cerebral Synthetic Magnetic Resonance Imaging (SyMRI)

  2. N-Acetyl-Aspartate (NAA) concentrations in the Brain [ Time Frame: 12 Months Post Dose ]
    N-Acetyl-Aspartate concentrations will be assessed with nuclear Magnetic Resonance Spectroscopy (nMRS) between pre- and post-treatment and as compared to historical controls.

  3. Neurological Evaluation - Motor Function [ Time Frame: 12 Months Post Dose ]
    Motor Function will be analyzed using the Gross Motor Function Measure (GMFM)-88 scale for motor function assessment before and after vector administration and compared to historical controls. The GMFM consists of 5 scales: Lying and Rolling, Sitting, Crawling and Kneeling, Standing and Walking, Running and Jumping. The total scores range from 0 to 264. The lower the score on GMFM, the weaker the ability; the higher the score, the greater the ability.

  4. Neurological Evaluation - Neurocognitive Function [ Time Frame: 12 Months Post Dose ]
    Neurocognitive function will be assessed using the Mullen Scales of Early Learning (MSEL) before and after vector administration and compared to historical controls. The MSEL is a cognitive test to measure cognitive ability and language development. The MSEL test has five scales: Gross motor, Visual reception, Fine motor, Receptive language, and Expressive language. The total scores range from 0 to 197. The lower the score on MSEL, the weaker the ability; the higher the score, the greater the ability.

  5. Neurological Evaluation - Spasticity [ Time Frame: 12 Months Post Dose ]
    Will be assessed using the Canavan Neurological Evaluation before and after vector administration and compared to historical controls.

  6. Seizure Assessment [ Time Frame: 12 Months Post Dose ]
    Will be assessed based on reported seizure activity and Electroencephalograms alpha, beta, delta, and theta wave frequencies (Hz).

  7. NAA concentration measured in Cerebrospinal Fluid (CSF) [ Time Frame: 6 months ]
    CSF will be collected via lumbar puncture and analyzed to assess concentrations of N-Acetyl-Aspartate.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Months to 60 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Definitive diagnosis of typical CD by a board certified neurologist.
  • Written informed consent from parent(s)/guardian(s). Consent to enroll into the study will include a written agreement to comply with all the conditions of the study, including attendance at follow-up visits.
  • For cohort 1: age more than 36 months and up to 60 months.
  • For cohort 2: age between 15 months and 36 months.
  • For cohort 3: age less than 15 months.

Exclusion Criteria:

  • At the discretion of the PI, any significant chronic medical condition, including, but not limited to neurological, cardiac, hepatic, renal, hematological, gastrointestinal, endocrine, pulmonary, or infectious disease, which would put the subject at increased risk during surgery or which would interfere with participation in the study, interpretation of safety monitoring, or the integrity of the study data.
  • History of severe allergic reaction or anaphylaxis.
  • Past participation in gene therapy trials or receipt of any other investigational product within 6 months prior to enrollment.
  • Prior intracranial surgery.
  • Any absolute contraindication to immunosuppression.
  • Any absolute contraindication to MRI.
  • Any vaccination less than 1 month prior to gene therapy.
  • Anticipated life expectancy of less than 12 months for any reason.
  • GMFM-88 total raw score >35%.
  • Clinically significant out-of-range lab values, at the discretion of clinical PI.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04833907

Layout table for location information
United States, Ohio
Dayton Children's Hospital
Dayton, Ohio, United States, 45404
Sponsors and Collaborators
Myrtelle Inc.
Layout table for investigator information
Principal Investigator: Christopher G Janson, MD Dayton Children's Hospital
Principal Investigator: Robert Lober, MD, PhD Dayton Children's Hospital
Additional Information:
Layout table for additonal information
Responsible Party: Myrtelle Inc.
ClinicalTrials.gov Identifier: NCT04833907    
Other Study ID Numbers: CAN-GT
First Posted: April 6, 2021    Key Record Dates
Last Update Posted: February 8, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Myrtelle Inc.:
Canavan Disease
Gene Therapy
Adeno-Associated Virus Vector
Autosomal Recessive Disorder
White Matter Disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Canavan Disease
Hereditary Central Nervous System Demyelinating Diseases
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Demyelinating Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Metabolism, Inborn Errors
Metabolic Diseases
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Nootropic Agents